31407-29-1 Usage
Uses
Used in Pharmaceutical Industry:
2-Aminoquinoline-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its unique combination of functional groups. The presence of the amino and carboxylic acid groups allows for versatile chemical reactions, facilitating the creation of a wide range of drug molecules with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-Aminoquinoline-3-carboxylic acid serves as a valuable building block for the development of new drug candidates. Its structural features enable the design and synthesis of compounds with specific biological activities, targeting various diseases and conditions.
Used in Drug Synthesis:
2-Aminoquinoline-3-carboxylic acid is utilized as a starting material in the synthesis of various drug molecules. Its reactivity and the presence of functional groups make it suitable for further chemical modifications, leading to the formation of pharmaceutically relevant compounds with desired properties.
Used in Drug Design:
In drug design, 2-Aminoquinoline-3-carboxylic acid is employed as a template for the development of novel therapeutic agents. Its structural attributes allow for the optimization of drug candidates, enhancing their potency, selectivity, and pharmacokinetic properties.
Used in Antimicrobial Agents:
2-Aminoquinoline-3-carboxylic acid is used as a component in the development of antimicrobial agents, particularly against resistant strains of bacteria and parasites. Its chemical properties enable the design of compounds with potent antimicrobial activity, addressing the growing need for new treatments in infectious diseases.
Used in Anticancer Agents:
2-Aminoquinoline-3-carboxylic acid is employed in the synthesis of anticancer agents, targeting various types of cancer cells. Its unique structure allows for the development of compounds with selective cytotoxicity, minimizing side effects and improving patient outcomes.
Used in Antimalarial Drugs:
2-Aminoquinoline-3-carboxylic acid is utilized in the development of antimalarial drugs, providing a potential alternative to existing treatments. Its structural features enable the design of compounds with high efficacy against Plasmodium parasites, the causative agents of malaria.
Check Digit Verification of cas no
The CAS Registry Mumber 31407-29-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,4,0 and 7 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 31407-29:
(7*3)+(6*1)+(5*4)+(4*0)+(3*7)+(2*2)+(1*9)=81
81 % 10 = 1
So 31407-29-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H8N2O2/c11-9-7(10(13)14)5-6-3-1-2-4-8(6)12-9/h1-5H,(H2,11,12)(H,13,14)
31407-29-1Relevant academic research and scientific papers
A new modification of the Friedlaender synthesis. A simple route to 2-aminoquinoline-3-carboxylic acid and its derivatives
Ukhin,Belov
experimental part, p. 418 - 421 (2009/06/06)
A new version of the Friedlaender synthesis of 2-aminoquinoline-3- carboxylic acid and its derivatives from stable 2-tosylaminobenzaldehyde or its morpholinal was proposed.
Carbapenem antibiotic compounds
-
, (2008/06/13)
The present invention relates to carbapenems and provides a compound of the formula (I) STR1 wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4 alkyl; R3 is hydrogen or C1-4 alkyl; P1 is of the formula: STR2 and one or two of A,B,C,D,E,F,G and H, are nitrogen and the remainder are CH; and P is bonded to the nitrogen of the linking carbamoyl group by a carbon atom, in either ring, is substituted by the carboxy group on a carbon atom, in either ring, and is optionally further substituted, by up to three substitutents, on a carbon atom, in either ring; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them are also described.
